AstraZeneca has entered into a definitive agreement with Foundation Medicine, Inc. (Foundation Medicine) to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global development programme.
The companion diagnostic will enable physicians to identify those patients mo